Swiss pharmaceutical giant Roche has announced a freeze on all future investment decisions in Germany, a move that casts a shadow over Berlin's efforts to revive Europe's largest economy. Daniel Steiners, head of Roche Germany, told Die Welt that the company is pausing expansion plans, citing a recent erosion of trust caused by political decisions affecting the pharmaceutical sector.
The announcement landed on the same day the German government opened a two-day investment summit in Berlin, intended to drum up business interest in the country. The timing could hardly be worse for Chancellor Olaf Scholz's administration, which is already grappling with sluggish growth, subdued domestic demand, and mounting external pressures.
Price cuts and trust deficit
At the heart of Roche's discontent is a law passed by German lawmakers in July, which forces pharmaceutical companies to grant steeper rebates on branded medicines. From next year, drugmakers must offer a 15.5% discount on most branded products, up from the current 7%. The measure is part of a broader effort to control costs in Germany's statutory health insurance system, which is under strain from an ageing population and rising healthcare expenditures.
Steiners was blunt in his assessment: "As far as the pharmaceutical sector is concerned, I can say that political decisions have recently destroyed a great deal of trust." His comments echo concerns raised by other industry players, who argue that the new rebate requirements undermine Germany's attractiveness as a location for research and production.
The United States has also taken note. In June, Washington launched a tariff probe into Germany, alleging that Berlin's policies constitute "persistent underpayment for innovative pharmaceutical products." That investigation adds another layer of uncertainty for companies like Roche, which operate globally and must weigh regulatory environments across multiple jurisdictions.
Government defends measures
Economy Minister Katherina Reiche defended the reforms, arguing that they are necessary to keep social security contributions from spiraling out of control. Speaking at the summit, she acknowledged the pharmaceutical industry's "enormous contributions" to the German economy, but insisted that cost containment is essential for the sustainability of the country's welfare state.
However, Reiche's reassurances did little to assuage concerns in the business community. Roland Busch, CEO of industrial giant Siemens, was present at the same press conference and described Roche's announcement as "a signal." His remark underscored a growing unease among corporate leaders about Germany's competitiveness, particularly in high-tech and innovation-driven sectors.
Germany's economic woes are not limited to pharmaceuticals. The country has posted minimal growth since the post-pandemic rebound of late 2022, as weak consumer spending at home combines with headwinds from US tariffs and intensifying competition from Chinese manufacturers. The automotive industry, a cornerstone of the German economy, is also facing disruption, with new EU rules on car emissions adding pressure to transition to electric vehicles.
Roche's decision is a reminder that Germany's challenges are not just cyclical but structural. The country's reliance on exports, its energy costs, and its bureaucratic hurdles are all factors that companies weigh when deciding where to invest. For a government that has made attracting foreign investment a priority, the freeze is a setback.
Steiners did not specify which projects are affected, but the scope of the pause suggests that Roche is reconsidering its long-term commitment to Germany. The company has significant operations in the country, including research facilities and production sites, and any scaling back could have ripple effects on local economies.
The investment summit, which continues through Tuesday, was meant to showcase Germany's strengths. Instead, it has become a platform for airing grievances. As Siemens' Busch hinted, the concerns raised by Roche are likely shared by other multinationals, and the government will need to address them if it hopes to reverse the tide.
For now, the message from Roche is clear: trust, once broken, is not easily restored. And in the competitive global race for investment, Germany can ill afford to lose the confidence of its most innovative industries.
